WVE 120102

Drug Profile

WVE 120102

Alternative Names: WVE-120102

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator WaVe life Sciences
  • Class Antisense oligonucleotides; Neuroprotectants
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Huntington's disease

Most Recent Events

  • 20 Feb 2018 Wave Life Sciences grants Takeda an option to co-develop and co-promote WVE 120102 for Huntington’s disease
  • 18 Jul 2017 Phase-I/II clinical trials in Huntington's disease in Canada (Intrathecal)
  • 16 Mar 2017 Preclinical trials in Huntington's disease in USA and Japan (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top